Provectus Biopharmaceuticals is focused on developing innovative immunotherapy medicines utilizing a proprietary class of small molecules known as halogenated xanthenes, which the company exclusively owns. Their lead compound, rose bengal disodium, is being explored for its therapeutic potential across various medical fields, including oncology, dermatology, hematology, virology, microbiology, and ophthalmology. The company emphasizes the importance of making these treatments safe, affordable, and accessible to patients globally, aiming to maximize their curative impact through diverse formulations and administration routes.

The company is currently advancing its drug development through clinical trials, specifically testing rose bengal in its PV-10 and PH-10 formulations. These trials are conducted in compliance with the U.S. Food and Drug Administration's Investigational New Drug Application (IND) requirements, ensuring that the research adheres to regulatory standards. Provectus also highlights the legal and health risks associated with the unapproved use of rose bengal outside of these regulated clinical settings, underscoring their commitment to patient safety and adherence to established medical protocols.

United States

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines based on small molecules called halogenated xanthenes, the entire class.

Provectus Biopharmaceuticals

Company Details